SGLT2 Inhibitors Market Size Worth USD 33.51 Billion by 2034 | CAGR: 6.9%

The global SGLT2 inhibitors market size is expected to reach USD 33.51 billion by 2034, according to a new study by Polaris Market Research. The report “SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], By Drug, By Distribution Channel, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors market has emerged as a significant segment of the global pharmaceutical industry, driven by the increasing prevalence of type 2 diabetes (T2D), heart failure, and chronic kidney disease (CKD). SGLT2 inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2, a protein responsible for reabsorbing glucose from the kidneys into the bloodstream

The market for SGLT2 inhibitors is experiencing significant growth due to their increasing efficacy in treating type 2 diabetes (T2D) by inhibiting glucose reabsorption in the kidneys and thereby lowering blood sugar levels. This expansion is attributed to the increasing obesity rates, sedentary lifestyles, aging populations, and unhealthy diets. Genetic predisposition, urbanization, and economic differences also contribute to the surge in diabetes cases in North America and globally. This is further contributing to the market growth.

Favorable reimbursement policies and regulatory approvals are driving market demand. Key players in the market are focusing on innovations in drug formulations to enhance their market positioning. Increased emphasis on the development of fixed-dose combination drugs is expected to create several market opportunities.

SGLT2 Inhibitors Market Report Insights

• North America accounted for a 37.32% revenue share in 2025. The rising prevalence of diabetes has led to increased demand for SGLT2 inhibitors in North America.
• Asia Pacific is anticipated to account for a CAGR of 7.5% during the projection period. The growing aging population has led to an increased incidence of type 2 diabetes in the region.
• The type 2 diabetes segment accounted for a market revenue share of 88.5% in 2025. The growing prevalence of obesity has resulted in a surge in type 2 diabetes cases.
• The online pharmacies segment is projected to witness the fastest growth, at a 7.9% CAGR. This is because online pharmacies offer unparalleled convenience to patients, especially those living in remote or underserved areas.
• Major players in the market include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.

Where is the Market Headed?

The SGLT2 inhibitors market is expected to grow steadily in the coming years. This growth is mainly due to the increasing number of people with type 2 diabetes. The use of these medicines is also increasing for other health problems, such as heart and kidney conditions, thereby boosting demand for these drugs. More doctors are prescribing these drugs because of their benefits beyond controlling blood sugar. At the same time, increased awareness and early treatment have increased the usage of the drug. The market is likely to increase as the need for effective treatments with multiple benefits continues.

What Does SGLT2 Inhibitors Report Reveals?

• What is the global SGLT2 inhibitors market size and CAGR for the market during 2026–2034?
• Which factors are contributing to the industry expansion?
• Who are the key industry players? What is their relative position in terms of competitive positioning?
• How do different distribution channels, such as hospital pharmacies and online pharmacies, influence the market landscape?
• How does the market differ in terms of indication, drug, distribution channel, and geography? Which is the leading indication?
• What are the opportunities in different regional markets, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
• What are the emerging technologies and innovations in the market?

Request a free sample copy or read the full market insights : SGLT2 Inhibitors Market Report

Polaris Market Research has segmented the SGLT2 inhibitors market report based on indication, drug, distribution channel, and region:

By Indication Outlook (Revenue, USD Billion, 2021–2034)

• Cardiovascular
• Chronic Kidney Disease (CKD)
• Type 2 Diabetes
• Others

By Drug Outlook (Revenue, USD Billion, 2021–2034)

• Farxiga (Dapagliflozin)
• Inpefa (Sotagliflozin)
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Qtern (Dapagliflozin/Saxagliptin)
• Other SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue, USD Billion, 2021–2034)

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Regional Outlook (Revenue, USD Billion, 2021–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America